{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:17:04Z","timestamp":1791044224508,"version":"4.1.0"},"publisher-location":"Vienna","reference-count":244,"publisher":"Springer Vienna","isbn-type":[{"value":"9783211832752","type":"print"},{"value":"9783709163603","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999]]},"DOI":"10.1007\/978-3-7091-6360-3_2","type":"book-chapter","created":{"date-parts":[[2012,10,6]],"date-time":"2012-10-06T01:06:34Z","timestamp":1349485594000},"page":"31-74","source":"Crossref","is-referenced-by-count":32,"title":["Pathogenesis and preclinical course of Parkinson\u2019s disease"],"prefix":"10.1007","author":[{"given":"P.","family":"Foley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Riederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"2_CR1","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/0006-2952(91)90646-M","volume":"41","author":"JD Adams","year":"1991","unstructured":"Adams JD, Odunze IN (1991) Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Biochem Pharmacol 41: 1099\u20131105","journal-title":"Biochem Pharmacol"},{"key":"2_CR2","first-page":"263","volume-title":"Advances in neurology, vol 69, Parkinson\u2019s disease","author":"S Aime","year":"1996","unstructured":"Aime S, Fasano M, Bergamasco B, Lopiano L, Quattrocolo G (1996) Nuclear magnetic resonance spectroscopy characterization and iron content determination of human mesencephalic neuromelanin. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69, Parkinson\u2019s disease. Lippincott-Raven, Philadelphia, pp 263\u2013270"},{"key":"2_CR3","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1046\/j.1471-4159.1997.69031196.x","volume":"69","author":"ZI Alam","year":"1997","unstructured":"Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B (1997) Oxidative DNA damage in the parkinsonian brain: a selective increase in 8-hydroxyguanine in substantia nigra? J Neurochem 69: 1196\u20131203","journal-title":"J Neurochem"},{"key":"2_CR4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1001\/archneur.1975.00490440064010","volume":"32","author":"LM Ambani","year":"1975","unstructured":"Ambani LM, Van Woert MH, Murphy S (1975) Brain peroxides and catalase in Parkinson\u2019s disease. Arch Neurol 32: 114\u2013118","journal-title":"Arch Neurol"},{"key":"2_CR5","first-page":"603","volume":"12","author":"P Anglade","year":"1997","unstructured":"Anglade P, Agid Y, Hirsch EC, Vyas S (1997) Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol 12: 603\u2013610","journal-title":"Histol Histopathol"},{"key":"2_CR6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00005072-198901000-00007","volume":"48","author":"C Bancher","year":"1989","unstructured":"Bancher C, Lassmann H, Budka H, Budka H, Jellinger K, Grundke-Iqbal I, Iqbal K, Wiche G, Seitelberger F, Wisniewski HM (1989) An antigenic profile of Lewy bodies: immunocytochemical indication for protein phosphorylation and ubiquitination. J Neuropathol Exp Neurol 48: 81\u201393","journal-title":"J Neuropathol Exp Neurol"},{"key":"2_CR7","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(85)90743-3","volume":"II","author":"A Barbeau","year":"1985","unstructured":"Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J (1985) Ecogenetics of Parkinson\u2019s disease: 4-hydroxylation of debrisoquine. Lancet II: 1213\u20131216","journal-title":"Lancet"},{"key":"2_CR8","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1212\/WNL.36.11.1490","volume":"36","author":"JA Baron","year":"1986","unstructured":"Baron JA (1986) Cigarette smoking and Parkinson\u2019s disease. Neurology 36: 1490\u20131496","journal-title":"Neurology"},{"key":"2_CR9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0166-2236(93)90117-5","volume":"16","author":"MF Beal","year":"1993","unstructured":"Beal MF, Hyman BT, Koroshetz W (1993) Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci 16: 125\u2013131","journal-title":"Trends Neurosci"},{"key":"2_CR10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0301-0082(94)90009-4","volume":"44","author":"KD Beck","year":"1994","unstructured":"Beck KD (1994) Functions of brain-derived neurotrophic factor, insulin-like growth factor-I and basic fibroblast growth factor in the development and maintenance of dopaminergic neurons. Prog Neurobiol 44: 497\u2013516","journal-title":"Prog Neurobiol"},{"key":"2_CR11","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1073\/pnas.87.4.1620","volume":"87","author":"JS Beckman","year":"1990","unstructured":"Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman PA (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and Superoxide. Proc Natl Acad Sci USA 87: 1620\u20131624","journal-title":"Proc Natl Acad Sci USA"},{"key":"2_CR12","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/j.1471-4159.1991.tb06432.x","volume":"57","author":"D Ben-Shachar","year":"1991","unstructured":"Ben-Shachar D, Youdim MBH (1991) Intranigral iron injection induces behavioral and biochemical \u201cParkinsonism\u201d in rats. J Neurochem 57: 2133\u20132135","journal-title":"J Neurochem"},{"key":"2_CR13","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1111\/j.1471-4159.1991.tb11444.x","volume":"56","author":"D Ben-Shachar","year":"1991","unstructured":"Ben-Shachar D, Eshel G, Finberg JPM, Youdim MBH (1991) The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal neurons. J Neurochem 56: 1441\u20131444","journal-title":"J Neurochem"},{"key":"2_CR14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/978-3-7091-2262-4_3","volume-title":"Die Parkinson-Krankheit: Biochemie, Klinik, Therapie","author":"W Birkmayer","year":"1985","unstructured":"Birkmayer W, Riederer P (1985) Die Parkinson-Krankheit: Biochemie, Klinik, Therapie 2nd edn. Springer, Wien New York, pp 60\u2013101","edition":"2"},{"key":"2_CR15","first-page":"139","volume":"46","author":"D Blum-Degen","year":"1995","unstructured":"Blum-Degen D, Fr\u00f6lich L, Hoyer S, Riederer P (1995) Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders? J Neural Transm [Suppl] 46: 139\u2013147","journal-title":"J Neural Transm [Suppl]"},{"key":"2_CR16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mds.870080202","volume":"8","author":"SB Blunt","year":"1993","unstructured":"Blunt SB, Jenner P, Marsden CD (1993) Suppressive effect of 1-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 8: 129\u2013133","journal-title":"Mov Disord"},{"key":"2_CR17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/BF00296485","volume":"88","author":"H Braak","year":"1994","unstructured":"Braak H, Braak E, Yilmazer D, de Vos RAI, Jansen ENH, Bohl J, Jellinger K (1994) Amygdala pathology in Parkinson\u2019s disease. Acta Neuropathol 88: 493\u2013500","journal-title":"Acta Neuropathol"},{"key":"2_CR18","first-page":"15","volume":"46","author":"H Braak","year":"1995","unstructured":"Braak H, Braak E, Yilmazer D, Schultz C, de Vos RAI, Jansen ENH (1995) Nigral and extranigral pathology in Parkinson\u2019s disease. J Neural Transm [Suppl] 46: 15\u201332","journal-title":"J Neural Transm [Suppl]"},{"key":"2_CR19","first-page":"25","volume-title":"Parkinson-Krankheit. Entwicklungen in Diagnostik und Therapie","author":"H Braak","year":"1997","unstructured":"Braak, H, Braak E, de Vos RAI, Jansen EHN, Bohl J (1997) Extranigrale Pathologie der Parkinson-Krankheit \u2014 limbisches System und vegetative Kerne. In: Fischer PA (ed) Parkinson-Krankheit. Entwicklungen in Diagnostik und Therapie. Schattauer, Stuttgart, pp 25\u201336"},{"key":"2_CR20","first-page":"235","volume":"46","author":"G Bringmann","year":"1995","unstructured":"Bringmann G, God R, Feineis D, Wesemann W, Riederer P, Rausch WD, Reichmann H, Sontag KH (1995) The TaClo concept: 1-trichloromethyl-1,2,3,4-tetrahydro-\u03b2-carboline (TaClo), a new toxin for dopaminergic neurons. J Neural Transm [Suppl] 46: 235\u2013244","journal-title":"J Neural Transm [Suppl]"},{"issue":"Suppl 2","key":"2_CR21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1212\/WNL.41.5_Suppl_2.24","volume":"41","author":"DJ Brookes","year":"1991","unstructured":"Brookes DJ (1991) Detection of preclinical Parkinson\u2019s disease with PET. Neurology 41(Suppl 2): 24\u201327","journal-title":"Neurology"},{"key":"2_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1054-3589(08)60961-8","volume":"23","author":"R Buccala","year":"1992","unstructured":"Buccala R, Cerami A (1992) Advanced glycosylation: chemistry, biology and implications for diabetes and aging. Adv Pharmacol 23: 1\u201334","journal-title":"Adv Pharmacol"},{"key":"2_CR23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1212\/WNL.44.1.5","volume":"44","author":"DB Calne","year":"1994","unstructured":"Calne DB (1994) Is idiopathic parkinsonism the consequence of an event or a process? Neurology 44: 5\u201310","journal-title":"Neurology"},{"key":"2_CR24","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1017\/S0317167100029905","volume":"16","author":"DB Calne","year":"1989","unstructured":"Calne DB, Eisen AA (1989) The relationship between Alzheimer\u2019s disease, Parkinson\u2019s disease and motoneuron disease. Can J Neurol Sci 16: 547\u2013550","journal-title":"Can J Neurol Sci"},{"key":"2_CR25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1017\/S0317167100026664","volume":"14","author":"S Calne","year":"1987","unstructured":"Calne S, Shoenberg BS, Martin W, Uitti RJ, Spencer P, Calne DB (1987) Familial Parkinson\u2019s disease: possible role of environmental factors. Can J Neurol Sci 14: 303\u2013315","journal-title":"Can J Neurol Sci"},{"issue":"Suppl 2","key":"2_CR26","first-page":"50","volume":"40","author":"A Carlsson","year":"1991","unstructured":"Carlsson A, Fornstedt B (1991) Catechol metabolites in the cerebrospinal fluid as possible markers in the early diagnosis of Parkinson\u2019s disease. Neurology 40(Suppl 2): 50\u201352","journal-title":"Neurology"},{"key":"2_CR27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0925-4439(91)90100-N","volume":"1097","author":"R Carstam","year":"1991","unstructured":"Carstam R, Brinck C, Hindemith-Augustsson A, Rorsman H, Rosengren E (1991) The neuromelanin of the human substantia nigra. Biochim Biophys Acta 1097: 152\u2013160","journal-title":"Biochim Biophys Acta"},{"key":"2_CR28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0006-8993(96)00729-9","volume":"737","author":"R Castellani","year":"1996","unstructured":"Castellani R, Smith MA, Richey PL, Perry G (1996) Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 737: 195\u2013200","journal-title":"Brain Res"},{"key":"2_CR29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0006-8993(92)90070-P","volume":"579","author":"K Chandrasekaran","year":"1992","unstructured":"Chandrasekaran K, Rapoport SI, Brady DR, Stoll J (1992) Localization of cytochrome oxidase (COX) activity and COX mRNA in the hippocampus and entorhinal cortex of the monkey brain: correlation with specific neuronal pathways. Brain Res 579: 333\u2013336","journal-title":"Brain Res"},{"key":"2_CR30","first-page":"297","volume":"2","author":"V Chan-Palay","year":"1991","unstructured":"Chan-Palay V, Zetzsche T, Hochli M (1991) Parvalbumin neurons in the hippocampus in senile dementia of the Alzheimer type, Parkinson\u2019s disease and multi-infarct dementia. Dementia 2: 297\u2013313","journal-title":"Dementia"},{"key":"2_CR31","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1471-4159.1992.tb09789.x","volume":"58","author":"MWJ Cleeter","year":"1992","unstructured":"Cleeter MWJ, Cooper JM, Schapira AHV (1992) Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 58: 786\u2013789","journal-title":"J Neurochem"},{"key":"2_CR32","first-page":"481","volume":"288","author":"MWJ Cleeter","year":"1994","unstructured":"Cleeter MWJ, Cooper JM, Darley-Usmar VM, Moncada S, Schapira AHV (1994) Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide: implications for neurodegenerative disorders. Acta Biochem Biophys 288: 481\u2013487","journal-title":"Acta Biochem Biophys"},{"key":"2_CR33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0304-3940(85)90016-3","volume":"55","author":"MA Collins","year":"1985","unstructured":"Collins MA, Neafsey EJ (1985) \u03b2-Carboline analogues of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism. Neurosci Lett 55: 179\u2013184","journal-title":"Neurosci Lett"},{"key":"2_CR34","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1471-4159.1995.65020717.x","volume":"65","author":"JR Connor","year":"1995","unstructured":"Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P (1995) A quantitative analysis of isoferritins in select regions of aged, parkinsonian and Alzheimer\u2019s diseased brains. J Neurochem 65: 717\u2013724","journal-title":"J Neurochem"},{"key":"2_CR35","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1126\/science.7901908","volume":"262","author":"JT Coyle","year":"1993","unstructured":"Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate and neurodegenerative disorders. Science 262: 689\u2013695","journal-title":"Science"},{"key":"2_CR36","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/327324a0","volume":"327","author":"RJ D\u2019Amato","year":"1987","unstructured":"D\u2019Amato RJ, Alexander GM, Schwartzman RJ, Kitt CA, Price DL, Snyder SH (1987) Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature 327: 324\u2013326","journal-title":"Nature"},{"key":"2_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0306-4522(93)90175-F","volume":"52","author":"P Damier","year":"1993","unstructured":"Damier P, Hirsch E, Javoy-Agid F, Zhang P, Agid Y (1993) Glutathione peroxidase, glial cells and Parkinson\u2019s disease. Neuroscience 52: 1\u20136","journal-title":"Neuroscience"},{"key":"2_CR38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0165-1781(79)90006-4","volume":"1","author":"GC Davis","year":"1979","unstructured":"Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat Res 1: 249\u2013254","journal-title":"Psychiat Res"},{"key":"2_CR39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ana.410320302","volume":"32","author":"TM Dawson","year":"1992","unstructured":"Dawson TM, Dawson VL, Snyder SH (1992) A novel neuronal messenger molecule in brain: the free radical, nitric oxide. Ann Neurol 32: 297\u2013311","journal-title":"Ann Neurol"},{"key":"2_CR40","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0163-7258(91)90029-L","volume":"52","author":"LD Leve De","year":"1991","unstructured":"DeLeve LD, Kaplowitz N (1991) Glutathione metabolism and its role in hepatotoxicity. Pharmacol Ther 52: 287\u2013305","journal-title":"Pharmacol Ther"},{"key":"2_CR41","first-page":"19","volume-title":"Advances in neurology, vol 69, Parkinson\u2019s disease","author":"G Michele De","year":"1996","unstructured":"De Michele G, Filla A, Volpe G, Gogliettino A, Ambrosio G, Campanella G (1996) Etiology of Parkinson\u2019s disease. The role of environment and heredity. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69, Parkinson\u2019s disease. Lippincott-Raven, Philadelphia, pp 19\u201324"},{"key":"2_CR42","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(87)91361-4","volume":"II","author":"DT Dexter","year":"1987","unstructured":"Dexter DT, Wells FR, Agid FJ (1987) Increased nigral iron content in postmortem parkinsonian brain. Lancet II: 1219\u20131220","journal-title":"Lancet"},{"key":"2_CR43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.1989.tb09133.x","volume":"52","author":"DT Dexter","year":"1989","unstructured":"Dexter DT, Cater CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantial nigra is increased in Parkinson\u2019s disease. J Neurochem 52: 381\u2013389","journal-title":"J Neurochem"},{"key":"2_CR44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1471-4159.1990.tb08814.x","volume":"55","author":"DT Dexter","year":"1990","unstructured":"Dexter DT, Carayon A, Vidailhet M, Ruberg M, Agid F, Agid Y, Lees AJ, Wells FR, Jenner P, Marsden CD (1990) Decreased ferritin levels in brain in Parkinson\u2019s disease. J Neurochem 55: 16\u201320","journal-title":"J Neurochem"},{"key":"2_CR45","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/brain\/114.4.1953","volume":"114","author":"DT Dexter","year":"1991","unstructured":"Dexter DT, Carayon A, Javoy-Agid F (1991) Alterations in the levels of iron, ferritin and other trace row diroudopically metals in Parkinson\u2019s disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114: 1953\u20131975","journal-title":"Brain"},{"key":"2_CR46","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ana.410320420","volume":"32","author":"DT Dexter","year":"1992","unstructured":"Dexter DT, Ward RJ, Wells FR, Daniel SE, Lees AJ, Peters IJ, Jenner P, Marsden CD (1992) \u03b1-Tocopherol levels in brain are not altered in Parkinson\u2019s disease. Ann Neurol 32: 591\u2013593","journal-title":"Ann Neurol"},{"key":"2_CR47","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/mds.870090115","volume":"9","author":"DT Dexter","year":"1994","unstructured":"Dexter DT, Holley AE, Flitter WD Slater TF, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD (1994a) Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 9: 92\u201397","journal-title":"Mov Disord"},{"key":"2_CR48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ana.410350107","volume":"35","author":"DT Dexter","year":"1994","unstructured":"Dexter DT, Sian J, Rose S, Hindmarsh JS, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Schapira AHV, et al (1994b) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 35: 38\u201344","journal-title":"Ann Neurol"},{"key":"2_CR49","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/WNL.42.2.402","volume":"42","author":"MC Difazio","year":"1992","unstructured":"Difazio MC, Hollingsworth Z, Young AB, Penney JBJ (1992) Glutamate receptors in the substantia nigra of Parkinson\u2019s disease brains. Neurology 42: 402\u2013406","journal-title":"Neurology"},{"issue":"Suppl 2","key":"2_CR50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1212\/WNL.41.5_Suppl_2.38","volume":"41","author":"DA DiMonte","year":"1991","unstructured":"DiMonte DA (1991) Mitochondrial DNA and Parkinson\u2019s disease. Neurology 41(Suppl 2): 38\u201342","journal-title":"Neurology"},{"key":"2_CR51","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF01245140","volume":"74","author":"P Dostert","year":"1988","unstructured":"Dostert P, Strolin-Benedetti M, Dordain G (1988) Dopamine-derived alkaloids in alcoholism and in Parkinson\u2019s and Huntington\u2019s disease. J Neural Transm 74: 61\u201374","journal-title":"J Neural Transm"},{"key":"2_CR52","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1212\/WNL.38.8.1237","volume":"38","author":"RL Doty","year":"1988","unstructured":"Doty RL, Deems DA, Stellar S (1988) Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38: 1237\u20131244","journal-title":"Neurology"},{"key":"2_CR53","first-page":"304","volume":"7","author":"KL Double","year":"1996","unstructured":"Double KL, Halliday GM, McRitchie DA, Reid WGJ, Hely MA, Morris JGL (1996) Regional brain atrophy in idiopathic Parkinson\u2019s disease and diffuse Lewy body disease. Dementia 7: 304\u2013313","journal-title":"Dementia"},{"key":"2_CR54","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1046\/j.1471-4159.1998.70062492.x","volume":"70","author":"KL Double","year":"1997","unstructured":"Double KL, Maywald M, Schmittel M, Riederer P, Gerlach M (1997) In vitro studies of ferritin iron release and neurotoxicity. J Neurochem 70: 2492\u20132499","journal-title":"J Neurochem"},{"key":"2_CR55","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00005072-196507000-00003","volume":"24","author":"PE Duffy","year":"1965","unstructured":"Duffy PE, Tennyson VM (1965) Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus coeruleus in Parkinson\u2019s disease. J Neuropathol Exp Neurol 24: 398\u2013414","journal-title":"J Neuropathol Exp Neurol"},{"key":"2_CR56","first-page":"33","volume-title":"Advances in neurology, vol 69, Parkinson\u2019s disease","author":"RC Duvoisin","year":"1996","unstructured":"Duvoisin RC (1996) Recent advances in the genetics of Parkinson\u2019s disease. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69, Parkinson\u2019s disease. Lippincott-Raven, Philadelphia, pp 33\u201340"},{"key":"2_CR57","first-page":"89","volume-title":"The scientific basis for the treatment of Parkinson\u2019s disease","author":"S Fahn","year":"1992","unstructured":"Fahn S (1992) Adverse effects of levodopa. In: Olanow CW, Lieberman AN (eds) The scientific basis for the treatment of Parkinson\u2019s disease. Parthenon, Carnforth (UK), pp 89\u2013112"},{"key":"2_CR58","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1111\/j.1471-4159.1993.tb03510.x","volume":"60","author":"BA Faucheaux","year":"1993","unstructured":"Faucheaux BA, Hirsch EC, Villares J, Selimi F, Mouatt-Prigent A, Javoy-Agid F, Agid Y (1993) Distribution of 125I-ferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson\u2019s disease. J Neurochem 60: 2238\u20132241","journal-title":"J Neurochem"},{"key":"2_CR59","doi-asserted-by":"crossref","first-page":"9303","DOI":"10.1073\/pnas.92.20.9303","volume":"92","author":"BA Faucheaux","year":"1995","unstructured":"Faucheaux BA, Nillesse N, Damier P, Spik G, Mouatt-Prigent A, Pierce A, Leveugle B, Kubis N, Hauw JJ, Agid Y, Hirsch EC (1995) Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson\u2019s disease. Proc Natl Acad Sci USA 92: 9303\u20139307","journal-title":"Proc Natl Acad Sci USA"},{"key":"2_CR60","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF01977355","volume":"65","author":"DJ Fawthrop","year":"1991","unstructured":"Fawthrop DJ, Boobis AR, Davies DS (1991) Mechanisms of cell death. Arch Toxicol 65: 437\u2013444","journal-title":"Arch Toxicol"},{"key":"2_CR61","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley JM, Lees A (1991) Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity. Brain 114: 2283\u20132301","journal-title":"Brain"},{"key":"2_CR62","first-page":"167","volume-title":"Advances in neurology, vol 69, Parkinson\u2019s disease","author":"F Fornai","year":"1996","unstructured":"Fornai F, Vaglini F, Maggio R, Bonuccelli U, Corsini GU (1996) Excitatory amino acids and MPTP toxicity. In: Battistin L, Scarlato G, Caraceni T, Ruggier\u0307i S (eds) Advances in neurology, vol 69, Parkinson\u2019s disease. Lippincott-Raven, Philadelphia, pp 167\u2013176"},{"key":"2_CR63","first-page":"65","volume-title":"Etiology of Parkinson\u2019s disease","author":"LS Forno","year":"1995","unstructured":"Forno LS (1995) Pathological considerations in the etiology of Parkinson\u2019s disease. In: Ellenberg JH. Koller WC, Langston JW (eds) Etiology of Parkinson\u2019s disease. Marcel Dekker, New York, pp 65\u201395"},{"key":"2_CR64","first-page":"19","volume":"2","author":"LS Forno","year":"1993","unstructured":"Forno LS, Langston JW (1993) Lewy bodies and aging: relation to Alzheimer\u2019s and Parkinson\u2019s diseases. Neurodegeneration 2: 19\u201324","journal-title":"Neurodegeneration"},{"key":"2_CR65","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/0304-3940(94)11164-E","volume":"184","author":"LS Forno","year":"1995","unstructured":"Forno LS, DeLanney LE, Irwin I, Langson JW (1995) Ultrastructure of eosinophilic inclusion bodies in the amygdala-parahippocampal region of aged squirrel monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic toxin. Neurosci Lett 184: 44\u201347","journal-title":"Neurosci Lett"},{"key":"2_CR66","first-page":"217","volume-title":"Advances in neurology, vol 53, Parkinson\u2019s disease: anatomy, pathology and therapy","author":"LS Forno","year":"1996","unstructured":"Forno LS, DeLanney LE, Irwin I, Langson JW (1996) Electron microscopy of Lewy bodies in the amygdala-parahippocampal region: comparison with inclusion bodies in the MPTP-treated squirrel monkey. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH (eds) Advances in neurology, vol 53, Parkinson\u2019s disease: anatomy, pathology and therapy. Raven Press, New York, pp 217\u2013228"},{"key":"2_CR67","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0166-2236(92)90103-F","volume":"15","author":"JL Franklin","year":"1992","unstructured":"Franklin JL, Johnson EM (1992) Suppression of programmed neuronal cell death by sustained elevation of cytosolic calcium. Trends Neurosci 15: 501\u2013508","journal-title":"Trends Neurosci"},{"key":"2_CR68","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/380252a0","volume":"380","author":"DM Gash","year":"1996","unstructured":"Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt GA (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380: 252\u2013255","journal-title":"Nature"},{"key":"2_CR69","first-page":"59","volume-title":"Parkinson-Krankheit. Entwicklungen in Diagnostik und Therapie","author":"T Gasser","year":"1997","unstructured":"Gasser T (1997) Stand der neurogenetischen Forschung bez\u00fcglich der Parkinson-Erkrankung. In: Fischer PA (ed) Parkinson-Krankheit. Entwicklungen in Diagnostik und Therapie. Schattauer, Stuttgart, pp 59\u201371"},{"key":"2_CR70","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/ana.410360310","volume":"36","author":"T Gasser","year":"1994","unstructured":"Gasser T, Wszolek ZK, Trofatter J, Ozelius L, Uitti RJ, Lee CS, Gusella J, Pfeiffer RF, Calne DB, Breakefield XO (1994) Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann Neurol 36: 387\u2013396","journal-title":"Ann Neurol"},{"key":"2_CR71","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-3-0348-6348-3_2","volume-title":"Inhibitors of monoamine oxidase","author":"M Gerlach","year":"1993","unstructured":"Gerlach M, Riederer P (1993) The pathophysiological basis of Parkinson\u2019s disease. In: Szelenyi (ed) Inhibitors of monoamine oxidase. Birkh\u00e4user, Basel, pp 25\u201350"},{"key":"2_CR72","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/BF01291788","volume":"103","author":"M Gerlach","year":"1996","unstructured":"Gerlach M, Riederer P (1996) Animal models of Parkinson\u2019s disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103: 987\u20131041","journal-title":"J Neural Transm"},{"key":"2_CR73","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0922-4106(91)90073-Q","volume":"208","author":"M Gerlach","year":"1991","unstructured":"Gerlach M, Riederer P, Przuntek H, Youdim MBH (1991) MPTP mechanisms of neurotoxicity and their implications for Parkinson\u2019s disease. Eur J Pharmacol [Mol Pharmacol Sect] 208: 273\u2013286","journal-title":"Eur J Pharmacol [Mol Pharmacol Sect]"},{"key":"2_CR74","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1471-4159.1994.63030793.x","volume":"63","author":"M Gerlach","year":"1994","unstructured":"Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63: 793\u2013807","journal-title":"J Neurochem"},{"key":"2_CR75","first-page":"177","volume-title":"Advances in neurology, vol 69, Parkinson\u2019s disease","author":"M Gerlach","year":"1996","unstructured":"Gerlach M, Riederer P, Youdim MBH (1996) Molecular mechanisms for neurodegeneration: synergism between reactive oxygen species, calcium and excitotoxic amino acids. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69, Parkinson\u2019s disease. Lippincott-Raven, Philadelphia, pp 177\u2013194"},{"key":"2_CR76","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1749-6632.1992.tb24523.x","volume":"648","author":"DC German","year":"1992","unstructured":"German DC, Manaye KF, Sonsalla PK, Brooks BA (1992) Midbrain dopaminergic cell loss in Parkinson\u2019s disease and MPTP-induced parkinsonism: sparing of calbindin D28k-containing cells. Ann NY Acad Sci 648: 42\u201362","journal-title":"Ann NY Acad Sci"},{"key":"2_CR77","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-3-7091-8994-8_20","volume-title":"Early diagnosis and preventative therapy in Parkinson\u2019s disease","author":"WRG Gibb","year":"1989","unstructured":"Gibb WRG (1989) The diagnostic relevance of Lewy bodies and other inclusions in Parkinson\u2019s disease. In: Przuntek H, Riederer P (eds) Early diagnosis and preventative therapy in Parkinson\u2019s disease. Springer, Wien New York, pp 171\u2013180"},{"key":"2_CR78","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0006-8993(92)90719-P","volume":"581","author":"WRG Gibb","year":"1992","unstructured":"Gibb WRG (1992) Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson\u2019s disease. Brain Res 581: 283\u2013291","journal-title":"Brain Res"},{"key":"2_CR79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2990.1989.tb01147.x","volume":"15","author":"WRG Gibb","year":"1989","unstructured":"Gibb WRG, Lees AJ (1989) The significance of the Lewy body in the diagnosis of idiopathic Parkinson\u2019s disease. Neuropathol Appl Neurobiol 15: 27\u201344","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2_CR80","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/brain\/110.5.1131","volume":"110","author":"WRG Gibb","year":"1985","unstructured":"Gibb WRG, Esiri MM, Lees AJ (1985) Clinical and pathologic features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 110: 1131\u20131153","journal-title":"Brain"},{"key":"2_CR81","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/mds.870060103","volume":"6","author":"WRG Gibb","year":"1991","unstructured":"Gibb WRG, Scott T, Lees AJ (1991) Neuronal inclusions of Parkinson\u2019s disease. Mov Disord 6: 2\u201311","journal-title":"Mov Disord"},{"key":"2_CR82","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0163-7258(94)90055-8","volume":"63","author":"ME G\u00f6tz","year":"1994","unstructured":"G\u00f6tz ME, Kiinig G, Riederer P, Youdim MBH (1994) Oxidative stress. Free radical production in neural degeneration. Pharmac Ther 63: 37\u2013122","journal-title":"Pharmac Ther"},{"key":"2_CR83","first-page":"115","volume-title":"Etiology of Parkinson\u2019s disease","author":"LI Golbe","year":"1995","unstructured":"Golbe LI (1995) Genetics of Parkinson\u2019s disease. In: Ellenberg JH, Koller WC, Langston JW (eds) Etiology of Parkinson\u2019s disease. Marcel Dekker, New York, pp 115\u2013140"},{"key":"2_CR84","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1212\/WNL.43.9.1641","volume":"43","author":"LI Golbe","year":"1993","unstructured":"Golbe LI, Lazzarini AM, Schwarz KO, Mark MH, Dickson DW, Duvoison RC (1993) Autosomal dominant parkinsonism with benign course and typical Lewy-body pathology. Neurology 43: 2222\u20132227","journal-title":"Neurology"},{"key":"2_CR85","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1126\/science.6308771","volume":"221","author":"JE Goldman","year":"1983","unstructured":"Goldman JE, Yen SH, Chiu FC, Peress NS (1983) Lewy bodies of Parkinson\u2019s disease contain neurofilament antigen. Science 221: 1082\u20131084","journal-title":"Science"},{"key":"2_CR86","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0006-8993(92)91334-B","volume":"593","author":"P Good","year":"1992","unstructured":"Good P, Olanow CW, Perl DP (1992) Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson\u2019s disease. A LAMMA study. Brain Res 593: 343\u2013346","journal-title":"Brain Res"},{"key":"2_CR87","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0026-895X(25)13535-9","volume":"14","author":"DG Graham","year":"1978","unstructured":"Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14: 633\u2013643","journal-title":"Mol Pharmacol"},{"key":"2_CR88","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0896-6273(95)90287-2","volume":"14","author":"LJ Greenlund","year":"1995","unstructured":"Greenlund LJ, Deckwerth TL, Johnson EMJ (1995) Superoxide dismutase delays neuronal aptosis: a role for reactive oxygen species in programmed neuronal death. Neuron 14: 303\u2013315","journal-title":"Neuron"},{"key":"2_CR89","first-page":"275","volume":"46","author":"C Grote","year":"1995","unstructured":"Grote C, Clement HW, Wesemann W, Bringmann G, Feineis D, Riederer P, Sontag KH (1995) Biochemical lesions of the nigrostriatal system by TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-\u03b2-carboline) and derivatives. J Neural Transm [Suppl] 46: 275\u2013281","journal-title":"J Neural Transm [Suppl]"},{"key":"2_CR90","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0005-2760(85)90113-4","volume":"835","author":"JM Gutteridge","year":"1985","unstructured":"Gutteridge JM, Quinlan GJ, Clark I, Halliwell B (1985) Aluminum salts accelerate peroxidation of membrane lipids stimulated by iron salts. Biochim Biophys Acta 835: 441\u2013447","journal-title":"Biochim Biophys Acta"},{"key":"2_CR91","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0006-8993(90)90733-R","volume":"510","author":"GM Halliday","year":"1990","unstructured":"Halliday GM, Blumberg PC, Cotton RGH, Blessing WW, Geffen LB (1990) Loss of brainstem serotonin-and substance P-containing neurons in Parkinson\u2019s disease. Brain Res 510: 104\u2013107","journal-title":"Brain Res"},{"key":"2_CR92","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/j.1471-4159.1992.tb10990.x","volume":"59","author":"B Halliwell","year":"1992","unstructured":"Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59: 1609\u20131623","journal-title":"J Neurochem"},{"key":"2_CR93","first-page":"889","volume":"5","author":"LA Hansen","year":"1992","unstructured":"Hansen LA, Galasko D (1992) Lewy body disease. Curr Opin Neurol Neurosurg 5: 889\u2013894","journal-title":"Curr Opin Neurol Neurosurg"},{"key":"2_CR94","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ana.410300409","volume":"30","author":"N Hattori","year":"1991","unstructured":"Hattori N, Tanaka M, Ozawa T, Mizuno Y (1991) Immunohistochemical studies on complexes I, II, III and IV of mitochondria in Parkinson\u2019s disease. Ann Neurol 30: 563\u2013571","journal-title":"Ann Neurol"},{"key":"2_CR95","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/neu.480251109","volume":"25","author":"F Hefti","year":"1994","unstructured":"Hefti F (1994) Neurotrophic factor therapy for central nervous system degenerative disease. J Neurobiol 25: 1418\u20131435","journal-title":"J Neurobiol"},{"key":"2_CR96","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1212\/WNL.31.9.1194","volume":"31","author":"F Hefti","year":"1981","unstructured":"Hefti F, Melamed E, Bhawan J, Wurtman R (1981) Long term administration of L-dopa does not damage dopaminergic neurons in the mouse. Neurology 31: 1194\u20131195","journal-title":"Neurology"},{"key":"2_CR97","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ng0897-325","volume":"16","author":"N Heintz","year":"1997","unstructured":"Heintz N, Zoghbi H (1997) \u03b1-synuclein \u2014 a link between Parkinson and Alzheimer diseases? Nat Genet 16: 325\u2013327","journal-title":"Nat Genet"},{"key":"2_CR98","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/cne.903090111","volume":"309","author":"W Hill","year":"1991","unstructured":"Hill W, Lee VMY, Hurtig H, Murray JM, Trojanowski JQ (1991) Epitopes located in spatially separated domains of each neurofilament subunit are present in Parkinson\u2019s disease Lewy bodies. J Comp Neurol 309: 150\u2013160","journal-title":"J Comp Neurol"},{"key":"2_CR99","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/334345a0","volume":"334","author":"EC Hirsch","year":"1988","unstructured":"Hirsch EC, Graybiel AM, Agid Y (1988) Melanized dopaminergic neurons are differentially affected in Parkinson\u2019s disease. Nature 334: 345\u2013348","journal-title":"Nature"},{"key":"2_CR100","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1471-4159.1991.tb08170.x","volume":"56","author":"EC Hirsch","year":"1991","unstructured":"Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson\u2019s disease: an X-ray microanalysis. J Neurochem 56: 446\u2013451","journal-title":"J Neurochem"},{"key":"2_CR101","first-page":"83","volume":"1","author":"EC Hirsch","year":"1992","unstructured":"Hirsch EC, Mouatt A, Thomasset M, Javoy-Agid F, Agid Y, Graybiel AM (1992) Expression of calbindin D28K-like immunoreactivity in catecholaminergic cell groups in the human midbrain. Normal distribution and distribution in Parkinson\u2019s disease. Neurodegeneration 1: 83\u201393","journal-title":"Normal distribution and distribution in Parkinson\u2019s disease. Neurodegeneration"},{"key":"2_CR102","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-3-7091-6842-4_9","volume":"50","author":"EC Hirsch","year":"1997","unstructured":"Hirsch EC, Faucheux B, Damier P, Mouatt-Prigent A, Agid Y (1997) Neuronal vulnerability in Parkinson\u2019s disease. J Neural Transm [Suppl] 50: 79\u201388","journal-title":"J Neural Transm [Suppl]"},{"key":"2_CR103","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/mds.870090304","volume":"9","author":"GS Hotamisligil","year":"1994","unstructured":"Hotamisligil GS, Girmen AS, Fink JS, Tivol E, Shalish C, Trofatter J, Baenziger J, Diamond S, Markham C, Sullivan J, et al (1994) Hereditary variations in the monoamine oxidase as a risk factor for Parkinson\u2019s disease. Mov Disord 9: 305\u2013310","journal-title":"Mov Disord"},{"key":"2_CR104","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0306-4522(95)00578-1","volume":"72","author":"S Hunot","year":"1996","unstructured":"Hunot S, Boissi\u00e8rre F, Faucheux B, Brugg B, Mouatt-Prigend A, Agid Y, Hirsch EC (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson\u2019s disease. Neuroscience 72: 355\u2013363","journal-title":"Neuroscience"},{"key":"2_CR105","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1073\/pnas.87.11.4078","volume":"87","author":"AM Iacopino","year":"1990","unstructured":"Iacopino AM, Christakos S (1990) Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci USA 87: 4078\u20134082","journal-title":"Proc Natl Acad Sci USA"},{"key":"2_CR106","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/0006-8993(89)90793-2","volume":"499","author":"Y Ichimaya","year":"1989","unstructured":"Ichimaya Y, Emson PC, Mountjoy CQ, Lawson DEM, Iizuka P (1989) Calbindin D28k-immunoreactive cholinergic neurons in the nucleus basalis of Meynert in Alzheimer-type dementia. Brain Res 499: 402\u2013406","journal-title":"Brain Res"},{"key":"2_CR107","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1615\/CritRevNeurobiol.v10.i2.50","volume":"10","author":"C Ikonomidou","year":"1996","unstructured":"Ikonomidou C, Turski L (1996) Neurodegenerative disorders: clues from glutamate and energy metabolism. Crit Rev Neurobiol 10: 239\u2013263","journal-title":"Crit Rev Neurobiol"},{"key":"2_CR108","first-page":"153","volume-title":"Etiology of Parkinson\u2019s disease","author":"I Irwin","year":"1995","unstructured":"Irwin I, Langston JW (1995) Endogenous toxins as potential etiologic agents in Parkinson\u2019s disease. In: Ellenberg JH, Koller WC, Langston JW (eds) Etiology of Parkinson\u2019s disease. Marcel Dekker, New York, pp 153\u2013201"},{"key":"2_CR109","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/mds.870120104","volume":"12","author":"K Itoh","year":"1997","unstructured":"Itoh K, Weis S, Mehraein P, Muller-Hocker J (1997) Defects of cytochrome c oxidase in the substantia nigra of Parkinson\u2019s disease: an immunohistochemical and morphometric study. Mov Disord 12: 9\u201316","journal-title":"Mov Disord"},{"key":"2_CR110","first-page":"265","volume":"46","author":"B Janetzky","year":"1995","unstructured":"Janetzky B, God R, Bringmann G, Reichmann H (1995) 1-Trichloromethyl-1,2,3,4-tetrahydro-\u03b2-carboline, a new inhibitor of complex I. J Neural Transm [Suppl] 46: 265\u2013273","journal-title":"J Neural Transm [Suppl]"},{"key":"2_CR111","first-page":"1","volume-title":"Advances in neurology, vol 53, Parkinson\u2019s disease: anatomy, pathology and therapy","author":"KA Jellinger","year":"1990","unstructured":"Jellinger KA (1990) New developments in the pathology of Parkinson\u2019s disease. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH (eds) Advances in neurology, vol 53, Parkinson\u2019s disease: anatomy, pathology and therapy. Raven Press, New York, pp 1\u201316"},{"key":"2_CR112","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF03159935","volume":"14","author":"KA Jellinger","year":"1991","unstructured":"Jellinger KA (1991) Pathology of Parkinson\u2019s disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 14: 153\u2013197","journal-title":"Mol Chem Neuropathol"},{"key":"2_CR113","first-page":"33","volume":"46","author":"KA Jellinger","year":"1995","unstructured":"Jellinger KA (1995) Neurodegenerative disorders with extrapyramidal features. J Neural Transm [Suppl] 46: 33\u201358","journal-title":"J Neural Transm [Suppl]"},{"key":"2_CR114","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/BF02252926","volume":"2","author":"P Jellinger","year":"1990","unstructured":"Jellinger P, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MBH (1990) Brain iron and ferritin in Parkinson\u2019s disease and Alzheimer\u2019s diseases. J Neural Transm [PD Sect] 2: 327\u2013340","journal-title":"J Neural Transm [PD Sect]"},{"key":"2_CR115","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/j.1471-4159.1992.tb08362.x","volume":"59","author":"K Jellinger","year":"1992","unstructured":"Jellinger K, Youdim MBH, Ben-Shachar D, Stachelberger H, Riederer P, Rumpelmair G, Kienzl E (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J Neurochem 59: 1168\u20131171","journal-title":"J Neurochem"},{"key":"2_CR116","first-page":"297","volume":"46","author":"K Jellinger","year":"1995","unstructured":"Jellinger K, Linert L, Kienzl E, Youdim MBH (1995) Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson\u2019s disease. J Neural Transm 46: 297\u2013314","journal-title":"J Neural Transm"},{"issue":"[Suppl3]","key":"2_CR117","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1212\/WNL.47.6_Suppl_3.161S","volume":"47","author":"P Jenner","year":"1996","unstructured":"Jenner P, Olanow CW (1996a) Oxidative stress and the pathogenesis of Parkinson\u2019s disease. Neurology 47 [Suppl 3]: S161\u2013S170","journal-title":"Neurology"},{"key":"2_CR118","first-page":"24","volume-title":"Neurodegeneration and neuroprotection in Parkinson\u2019s disease","author":"P Jenner","year":"1996","unstructured":"Jenner P, Olanow CW (1996b) Pathological evidence for oxidative stress in Parkinson\u2019s disease and related degenerative disorders. In: Olanow CW, Jenner P, Youdim M (eds) Neurodegeneration and neuroprotection in Parkinson\u2019s disease. Academic Press, London, pp 24\u201345"},{"key":"2_CR119","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/mds.870050302","volume":"5","author":"WG Johnson","year":"1990","unstructured":"Johnson WG, Hodge SE, Duvoisin RC (1990) Twin studies and the genetics of Parkinson\u2019s disease \u2014 a reappraisal. Mov Disord 5: 187\u2013194","journal-title":"Mov Disord"},{"key":"2_CR120","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0003-9861(88)90509-7","volume":"260","author":"GEN Kass","year":"1988","unstructured":"Kass GEN, Wright JM, Nicotera P, Orrenius S (1988) The mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: role of intracellular calcium. Arch Biochem Biophys 260: 789\u2013797","journal-title":"Arch Biochem Biophys"},{"key":"2_CR121","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0304-3940(85)90078-3","volume":"58","author":"SJ Kish","year":"1985","unstructured":"Kish SJ, Morito CH, Hornykiewicz O (1985) Glutathione peroxidase activity in Parkinson\u2019s disease brain. Neurosci Lett 58: 343\u2013346","journal-title":"Neurosci Lett"},{"key":"2_CR122","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ana.410340413","volume":"34","author":"T Klockgether","year":"1993","unstructured":"Klockgether T, Turski L (1993) Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia. Ann Neurol 34: 585\u2013593","journal-title":"Ann Neurol"},{"issue":"[Suppl1]","key":"2_CR123","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1212\/WNL.49.1_Suppl_1.S10","volume":"49","author":"WC Koller","year":"1997","unstructured":"Koller WC, Montgomery EB (1997) Issues in the early diagnosis of Parkinson\u2019s disease. Neurology 49 [Suppl 1]: S10\u2013S25","journal-title":"Neurology"},{"key":"2_CR124","first-page":"465","volume":"48","author":"K Kondo","year":"1973","unstructured":"Kondo K, Kurland RT (1973) Parkinson\u2019s disease, genetic analysis and evidence of a multifactorial etiology. Mayo Clin Proc 48: 465\u2013474","journal-title":"Mayo Clin Proc"},{"key":"2_CR125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF00690978","volume":"42","author":"K Kosaka","year":"1978","unstructured":"Kosaka K (1978) Lewy bodies in the cerebral cortex: report of three cases. Acta Neuropathol (Berl) 42: 127\u2013134","journal-title":"Acta Neuropathol (Berl)"},{"key":"2_CR126","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/(SICI)1097-4547(19960415)44:2<174::AID-JNR10>3.0.CO;2-6","volume":"44","author":"S Kosel","year":"1996","unstructured":"Kosel S, Lucking SB, Egensperger R, Mehraein P, Graeber MB (1996) Mitochondrial NADH dehydrogenase and CYP2D6 genotypes in Lewy-body parkinsonism. J Neurosci Res 44: 174\u2013183","journal-title":"J Neurosci Res"},{"key":"2_CR127","first-page":"229","volume":"46","author":"W Kuhn","year":"1995","unstructured":"Kuhn W, M\u00fcller T (1995) Neuroimmune mechanisms in Parkinson\u2019s disease. J Neural Transm [Suppl] 46: 229\u2013234","journal-title":"J Neural Transm [Suppl]"},{"key":"2_CR128","first-page":"87","volume-title":"Parkinson-Krankheit. Entwicklungen in Diagnostik und Therapie","author":"W Kuhn","year":"1997","unstructured":"Kuhn W, M\u00fcller T (1997) Hypersusceptibilit\u00e4t gegen Xenobiotika. Die potentielle Bedeutung \u00f6kogenetischer Faktoren f\u00fcr die Atiologie des Morbus Parkinson. In: Fischer PA (ed) Parkinson-Krankheit. Entwicklungen in Diagnostik und Therapie. Schattauer, Stuttgart, pp 87\u201393"},{"key":"2_CR129","first-page":"291","volume":"46","author":"W Kuhn","year":"1995","unstructured":"Kuhn W, M\u00fcller T, Gro\u03b2e H, Rommelspacher H (1995) Plasma harman and norharman in Parkinson\u2019s disease. J Neural Transm [Suppl] 46: 291\u2013295","journal-title":"J Neural Transm [Suppl]"},{"key":"2_CR130","first-page":"193","volume":"46","author":"A Kupsch","year":"1995","unstructured":"Kupsch A, Oertel WH, Earl CD, Sautter J (1995) Neuronal transplantation and neurotrophic factors in the treatment of Parkinson\u2019s disease \u2014 update February 1995. J Neural Transm [Suppl] 46: 193\u2013207","journal-title":"J Neural Transm [Suppl]"},{"key":"2_CR131","first-page":"368","volume":"33","author":"JH Kurth","year":"1993","unstructured":"Kurth JH, Kurth MC, Poduslo SE, Schwankhaus JD (1993) Association of a monoamine oxidase B allele with Parkinson\u2019s disease. Neurology 33: 368\u2013372","journal-title":"Neurology"},{"key":"2_CR132","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0022-510X(91)90261-5","volume":"106","author":"PW Landfield","year":"1991","unstructured":"Landfield PW, Applegate MD, Schwitzer-Osborne SE, Naylor CE (1991) Phosphate\/ calcium alterations in the first stages of Alzheimer\u2019s disease: Implications for etiology and pathogenesis. J Neurol Sci 106: 221\u2013229","journal-title":"J Neurol Sci"},{"key":"2_CR133","first-page":"61","volume-title":"Advances in neurology, vol 69, Parkinson\u2019s disease","author":"MT Landi","year":"1996","unstructured":"Landi MT, Ceroni M, Martignoni E, Bertazzi PA, Caporaso NE, Nappi G (1996) Gene-environment action in Parkinson\u2019s disease. The case of CYP2D6 polymorphism. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69, Parkinson\u2019s disease. Lippincott-Raven, Philadelphia, pp 61\u201372"},{"issue":"[Suppl3]","key":"2_CR134","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1212\/WNL.47.6_Suppl_3.153S","volume":"47","author":"JW Langston","year":"1996","unstructured":"Langston JW (1996) The etiology of Parkinson\u2019s disease with emphasis on the MPTP story. Neurology 47 [Suppl 3]: S153\u2013S160","journal-title":"Neurology"},{"key":"2_CR135","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1126\/science.6823561","volume":"219","author":"JW Langston","year":"1983","unstructured":"Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 970\u2013980","journal-title":"Science"},{"key":"2_CR136","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1212\/WNL.44.3_Part_1.499","volume":"44","author":"AM Lazzarini","year":"1994","unstructured":"Lazzarini AM, Myers RH, Zimmerman TR, Mark MH, Golbe JI, Sage JI, Johnson WG, Duvoisin RC (1994) A clinical genetic study of Parkinson\u2019s disease: evidence for dominant transmission. Neurology 44: 499\u2013506","journal-title":"Neurology"},{"key":"2_CR137","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/brain\/117.3.501","volume":"117","author":"CS Lee","year":"1994","unstructured":"Lee CS, Schulzer M, Mak E, Snow BJ, Tsui JK, Calne S, Hammerstad J, Calne B (1994) Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 117: 501\u2013507","journal-title":"Brain"},{"key":"2_CR138","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00308959","volume":"79","author":"P Leigh","year":"1989","unstructured":"Leigh P, Probst A, Gale G, Dale GE, Power DP, Brion JP, Dodson A, Anderton BH (1989) New aspects of the pathology of neurodegenerative disorders as revealed by ubiquitin antibodies. Acta Neuropathol (Berl) 79: 61\u201372","journal-title":"Acta Neuropathol (Berl)"},{"key":"2_CR139","doi-asserted-by":"crossref","unstructured":"Leveugle B, Faucheux BA, Bouras C, Nillesse N, Spik G, Hirsch EC, Agid Y, Hof PR (1996) Immunohistochemical analysis of the iron binding protein lactotransferrin in the mesencephalon of Parkinson\u2019s disease cases. Acta Neuropathol 566\u2013572","DOI":"10.1007\/s004010050468"},{"key":"2_CR140","first-page":"920","volume-title":"Handbuch der Neurologie","author":"FH Lewy","year":"1912","unstructured":"Lewy FH (1912) Paralysis agitans. I. Pathologische Anatomie. In: Lewandowsky M (ed) Handbuch der Neurologie, vol III. Springer, Berlin, pp 920\u2013933"},{"key":"2_CR141","doi-asserted-by":"crossref","unstructured":"Lindquist NG, Larsson BS, Lyden-Sokolowski A (1987) Neuromelanin and its possible protective and destructive properties. Pigment Cell Res: 133\u2013136","DOI":"10.1111\/j.1600-0749.1987.tb00403.x"},{"key":"2_CR142","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0047-6374(83)90074-X","volume":"21","author":"DMA Mann","year":"1983","unstructured":"Mann DMA, Yates PO (1983) Possible role of neuromelanin in the pathogenesis of Parkinson\u2019s disease. Mech Age Dev 21: 193\u2013203","journal-title":"Mech Age Dev"},{"key":"2_CR143","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00005072-197703000-00012","volume":"36","author":"DMA Mann","year":"1977","unstructured":"Mann DMA, Yates PO, Barton CM (1977) Neuromelanin and RNA in cells of substantia nigra. J Neuropathol Exp Neurol 36: 379\u2013383","journal-title":"J Neuropathol Exp Neurol"},{"key":"2_CR144","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/ana.410360612","volume":"36","author":"VM Mann","year":"1994","unstructured":"Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, Schapira AH (1994) Complex I, iron and ferritin in Parkinson\u2019s disease substantia nigra. Ann Neurol 36: 876\u2013881","journal-title":"Ann Neurol"},{"key":"2_CR145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/mds.870060303","volume":"6","author":"DM Maraganore","year":"1991","unstructured":"Maraganore DM, Harding AE, Marsden CD (1991) A clinical and genetic study of familial Parkinson\u2019s disease. Mov Disord 6: 205\u2013211","journal-title":"Mov Disord"},{"key":"2_CR146","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0022-510X(85)90156-X","volume":"67","author":"S Marklund","year":"1985","unstructured":"Marklund S, Adolfsson R, Gottfries C, Winblad B (1985) Superoxide dismutase isoenzymes in normal brains and in brains from patients with dementia of Alzheimer type. J Neurol Sci 67: 319\u2013325","journal-title":"J Neurol Sci"},{"key":"2_CR147","first-page":"121","volume":"19","author":"CD Marsden","year":"1983","unstructured":"Marsden CD (1983) Neuromelanin and Parkinson\u2019s disease. J Neural Transm [Suppl] 19: 121\u2013141","journal-title":"J Neural Transm [Suppl]"},{"key":"2_CR148","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF01664011","volume":"51","author":"RJ Martilla","year":"1981","unstructured":"Martilla RJ, Rinne UK (1981) Epidemiology of Parkinson\u2019s disease: an overview. J Neural Transm 51: 135\u2013148","journal-title":"J Neural Transm"},{"key":"2_CR149","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0022-510X(88)90108-6","volume":"86","author":"RJ Martilla","year":"1988","unstructured":"Martilla RJ, Lorentz H, Rinne UK (1988) Oxygen toxicity protecting enzymes in Parkinson\u2019s disease: increase of Superoxide dismutase-like activity in the substantial nigra and basal nucleus. J Neurol Sci 86: 321\u2013331","journal-title":"J Neurol Sci"},{"key":"2_CR150","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1212\/WNL.45.12.2240","volume":"45","author":"K Matsubara","year":"1995","unstructured":"Matsubara K, Koyabashi S, Koyabashi Y, Yamashita K, Koide H, Hatta M, Iwamoto K, Tanaka O, Kimura K (1995) \u03b2-Carbolinium cations, endogenous MPP+ analogs, in the lumbar cerebrospinal fluid of patients with Parkinson\u2019s disease. Neurology 45: 2240\u20132245","journal-title":"Neurology"},{"key":"2_CR151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-6147(92)90002-N","volume":"13","author":"T McCall","year":"1991","unstructured":"McCall T, Vallance P (1991) Nitric oxide takes center stage with newly defined roles. Trends Pharmacol Sci 13: 1\u20136","journal-title":"Trends Pharmacol Sci"},{"key":"2_CR152","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.410240415","volume":"24","author":"PL McGeer","year":"1988","unstructured":"McGeer PL, Itagaki S, Akiyama K, McGeer EG (1988) Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24: 574\u2013576","journal-title":"Ann Neurol"},{"key":"2_CR153","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0891-5849(90)90148-C","volume":"8","author":"DM Miller","year":"1990","unstructured":"Miller DM, Buettner GR, Aust SD (1990) Transition metals as catalysts of auto-oxidation reactions. Free Radical Biol Med 8: 95\u2013108","journal-title":"Free Radical Biol Med"},{"key":"2_CR154","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ana.410350212","volume":"35","author":"Y Mizuno","year":"1994","unstructured":"Mizuno Y, Matuda S, Yoshino H, Mori H, Hattori N, Ikebe SI (1994) An immunohistochemical study on \u03b1-ketoglutarate dehydrogenase complex in Parkinson\u2019s disease. Ann Neurol 35: 204\u2013210","journal-title":"Ann Neurol"},{"key":"2_CR155","first-page":"1","volume":"54","author":"H Mj\u00f6nes","year":"1949","unstructured":"Mj\u00f6nes H (1949) Paralysis agitans: a clinical and genetic study. Acta Psychiatr Neurol 54: 1\u201395","journal-title":"Acta Psychiatr Neurol"},{"key":"2_CR156","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0022-510X(95)00336-Z","volume":"137","author":"H Mochizuki","year":"1996","unstructured":"Mochizuki H, Goto K, Mori H, Mizuno Y (1996) Histochemical detection of apoptosis in Parkinson\u2019s disease. J Neurol Sci 137: 120\u2013123","journal-title":"J Neurol Sci"},{"key":"2_CR157","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0304-3940(96)13257-2","volume":"220","author":"M Mogi","year":"1996","unstructured":"Mogi M, Harada M, Kondo T, Mizuno Y, Narabayashi H, Riederer P, Nagatsu T (1996) The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neurosci Lett 220: 195\u2013198","journal-title":"Neurosci Lett"},{"key":"2_CR158","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF00313602","volume":"87","author":"I Moroo","year":"1994","unstructured":"Moroo I, Yamada T, Makino H, Tooyama I, McGeer PL, McGeer EG, Hirayama K (1994) Loss of insukin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson\u2019s disease. Acta Neuropathol 87: 343\u2013348","journal-title":"Acta Neuropathol"},{"key":"2_CR159","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/brain\/119.2.585","volume":"119","author":"PK Morrish","year":"1996","unstructured":"Morrish PK, Sawle GV, Brooks PJ (1996) An [18F]dopa PET and clinical study of the rate of progression in Parkinson\u2019s disease. Brain 119: 585\u2013591","journal-title":"Brain"},{"key":"2_CR160","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/0306-4522(96)00100-5","volume":"73","author":"A Mouant-Prigent","year":"1996","unstructured":"Mouant-Prigent A, Karlsson JO, Agid Y, Hirsch EC (1996) Increased m-calpain expression in the mesencephalon of patients with Parkinson\u2019s disease but not in other neurodegenerative disorders involving the mesencephalon: a role in cell death? Neuroscience 73: 979\u2013987","journal-title":"Neuroscience"},{"key":"2_CR161","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0165-0173(96)00016-1","volume":"23","author":"G M\u00fcnch","year":"1997","unstructured":"M\u00fcnch G, Thome J, Foley P, Schinzel R, Riederer P (1997) Advanced glycation end products in ageing and disease. Brain Res Rev 23: 134\u2013143","journal-title":"Brain Res Rev"},{"key":"2_CR162","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/00001756-199402000-00011","volume":"5","author":"EJ Mufson","year":"1994","unstructured":"Mufson EJ, Brandabur MM (1994) Sparing of NADPH-diaphorase striatal neurons in Parkinson\u2019s and Alzheimer\u2019s diseases. Neuroreport 5: 705\u2013708","journal-title":"Neuroreport"},{"key":"2_CR163","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0006-8993(86)91207-2","volume":"377","author":"N Nishino","year":"1986","unstructured":"Nishino N, Noguchi-Kuno SA, Sugiyama T, Tanaka C (1986) [3H]Nitrendipine binding sites are decreased in the substantia nigra and striatum of the brain from patients with Parkinson\u2019s disease. Brain Res 377: 186\u2013189","journal-title":"Brain Res"},{"key":"2_CR164","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/hmg\/6.10.1687","volume":"6","author":"RL Nussbaum","year":"1997","unstructured":"Nussbaum RL, Polymeropoulos MH (1997) Genetics of Parkinson\u2019s disease. Hum Mol Genet 6: 1687\u20131691","journal-title":"Hum Mol Genet"},{"key":"2_CR165","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0006-8993(94)90833-8","volume":"660","author":"E Oestreicher","year":"1994","unstructured":"Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash G (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron in within the substantia nigra: a histochemical and neurochemical study. Brain Res 660: 8\u201318","journal-title":"Brain Res"},{"key":"2_CR166","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0197-0186(96)00150-7","volume":"31","author":"D Offen","year":"1997","unstructured":"Offen D, Ziv I, Barzilai A, Gorodin S, Glater E, Hochman A, Melamed E (1997) Dopamine-melanin induces apoptosis in PC12 cells: possible implications for etiology of Parkinson\u2019s disease. Neurochem Int 31: 207\u2013216","journal-title":"Neurochem Int"},{"issue":"[Suppl1]","key":"2_CR167","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1212\/WNL.49.1_Suppl_1.S26","volume":"49","author":"CW Olanow","year":"1997","unstructured":"Olanow CW (1997) Attempts to obtain neuroprotection in Parkinson\u2019s disease. Neurology 49 [Suppl 1]: S26\u2013S33","journal-title":"Neurology"},{"key":"2_CR168","first-page":"95","volume-title":"Kainic acid as a tool in neurobiology","author":"JW Olney","year":"1978","unstructured":"Olney JW (1978) Neurotoxicity of excitatory amino acids. In: McGeer EG, Olney JW (eds) Kainic acid as a tool in neurobiology. Raven, New York, pp 95\u2013121"},{"key":"2_CR169","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0006-3223(89)90072-3","volume":"26","author":"JW Olney","year":"1989","unstructured":"Olney JW (1989) Excitatory amino acids and neuropsychiatric disorders. Biol Psychiatry 26: 505\u2013525","journal-title":"Biol Psychiatry"},{"key":"2_CR170","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0166-2236(97)01098-9","volume":"20","author":"L Olson","year":"1997","unstructured":"Olson L (1997) The coming of age of the GDNF family and its receptors: gene delivery in a rat Parkinson model may have clinical implications. Trends Neurosci 20: 277\u2013279","journal-title":"Trends Neurosci"},{"key":"2_CR171","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/00005072-199111000-00006","volume":"50","author":"W Paulus","year":"1991","unstructured":"Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson\u2019s disease. J Neuropathol Exp Neurol 50: 743\u2013755","journal-title":"J Neuropathol Exp Neurol"},{"key":"2_CR172","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/BF01291884","volume":"104","author":"RKB Pearce","year":"1997","unstructured":"Pearce RKB, Owen A, Daniel S, Jenner P, Marsden CD (1997) Alterations in the distribution of glutathione in the substantia nigra in Parkinson\u2019s disease. J Neural Transm 104: 661\u2013677","journal-title":"J Neural Transm"},{"key":"2_CR173","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0304-3940(82)90390-1","volume":"33","author":"TL Perry","year":"1982","unstructured":"Perry TL, Goden DV, Hansen S (1982) Parkinson\u2019s disease: a disorder due to nigral glutathione deficiency. Neurosci Lett 33: 305\u2013310","journal-title":"Neurosci Lett"},{"key":"2_CR174","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1471-4159.1984.tb12834.x","volume":"43","author":"TL Perry","year":"1984","unstructured":"Perry TL, Young VW, Ito M, Foulks JG, Wall RA, Godin DV, Clavier RM (1984) Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-dopa and carbidopa chronically. J Neurochem 43: 990\u2013993","journal-title":"J Neurochem"},{"key":"2_CR175","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0022-510X(90)90037-N","volume":"100","author":"RH Perry","year":"1990","unstructured":"Perry RH, Irving D, Tomlinson BE (1990) Lewy body prevalence in the aging brain: relationship to neuropsychiatric disorders, Alzheimer-type pathology and catecholaminergic nuclei. J Neurol Sci 100: 223\u2013233 (published erratum in J Neural Sci (1991) 102:121)","journal-title":"J Neurol Sci"},{"key":"2_CR176","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0896-6273(91)90273-3","volume":"7","author":"HS Phillips","year":"1991","unstructured":"Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW (1991) BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer\u2019s disease. Neuron 7: 695\u2013702","journal-title":"Neuron"},{"key":"2_CR177","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0006-8993(91)91734-I","volume":"565","author":"MA Pigott","year":"1991","unstructured":"Pigott MA, Candy JM, Perry RH (1991) [3H]Nitrendipine binding in temporal cortex in Alzheimer\u2019s and Huntington\u2019s diseases. Brain Res 565: 42\u201347","journal-title":"Brain Res"},{"key":"2_CR178","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0891-5849(88)90049-4","volume":"4","author":"B Pilas","year":"1988","unstructured":"Pilas B, Sarna T, Kalyanaraman B, Swartz RM (1988) The effect of melanin on iron associated decomposition of hydrogen peroxide. Free Radical Biol Med 4: 285\u2013293","journal-title":"Free Radical Biol Med"},{"key":"2_CR179","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1471-4159.1989.tb02550.x","volume":"52","author":"E Pileblad","year":"1996","unstructured":"Pileblad E, Magnusson T, Fornstedt B (1996) Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-hydroxydopamine in rat striatum. J Neurochem 52: 978\u2013980","journal-title":"J Neurochem"},{"key":"2_CR180","first-page":"215","volume":"19","author":"W Poewe","year":"1983","unstructured":"Poewe W, Gerstenbrand F, Ransmayr G, Plorer S (1983) Premorbid personality of Parkinsonian patients. J Neural Transm [Suppl] 19: 215\u2013224","journal-title":"J Neural Transm [Suppl]"},{"key":"2_CR181","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lowedern C, Leroy E, Ide SE, Dehija A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al (1997) Mutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease. Science 276: 2045\u20132047","journal-title":"Science"},{"key":"2_CR182","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1523\/JNEUROSCI.12-05-01658.1992","volume":"12","author":"S Przedborski","year":"1992","unstructured":"Przedborski S, Kostic V, Jackson-Lewis V, Naini AB, Simonetti S, Fahn S, Carlson E, Epstein CJ, Cadet JL (1992) Transgenic mice with increased Cu\/Zn-superoxide dismutase activity are resistant to MPTP-induced neurotoxicity. J Neurosci 12: 1658\u20131667","journal-title":"J Neurosci"},{"key":"2_CR183","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.410340515","volume":"34","author":"S Przedborski","year":"1993","unstructured":"Przedborski S, Jackson-Lewis V, Muthane U, Jiang H, Ferreira M, Naini AB, Fahn S (1993) Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 34: 715\u2013723","journal-title":"Ann Neurol"},{"key":"2_CR184","first-page":"259","volume-title":"Parkinson-Krankheit. Entwicklungen in Diagnostik und Therapie","author":"H Przuntek","year":"1997","unstructured":"Przuntek H, M\u00fcller T, Kuhn W, Hoffmann V (1997) Ist Apoptose, ein zentraler Mechanismus der Neurodegeneration, durch Selegiline beeinflu\u00dfbar? In: Fischer PA (ed) Parkinson-Krankheit. Entwicklungen in Diagnostik und Therapie. Schattauer, Stuttgart, pp 259\u2013274"},{"key":"2_CR185","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/0003-9861(91)90224-7","volume":"288","author":"R Radi","year":"1991","unstructured":"Radi R, Beckman JS, Bush KM, Freeman BA (1991) Peroxynitrite-induced membrane peroxidation: the cytotoxic potential of Superoxide and nitric oxide. Arch Biochem Biophys 288: 481\u2013487","journal-title":"Arch Biochem Biophys"},{"key":"2_CR186","first-page":"297","volume-title":"Advances in neurology, vol 60, Parkinson\u2019s disease: from basic research to treatment","author":"H Reichmann","year":"1993","unstructured":"Reichmann H, Lestienne P, Jellinger K, Riederer P (1993) Parkinson\u2019s disease and the electron transport chain in post mortem brain. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (eds) Advances in neurology, vol 60, Parkinson\u2019s disease: from basic research to treatment. Raven, New York, pp 297\u2013299"},{"key":"2_CR187","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0003-9861(90)90680-W","volume":"283","author":"DW Reif","year":"1990","unstructured":"Reif DW, Simmons RD (1990) Nitric oxide mediates iron release from ferritin. Arch Biochem Biophys 283: 537\u2013541","journal-title":"Arch Biochem Biophys"},{"key":"2_CR188","volume-title":"Iron in central nervous system disorders","year":"1993","unstructured":"Riederer P, Youdim MBH (eds) (1993) Iron in central nervous system disorders. Springer, Wien New York"},{"key":"2_CR189","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF01249445","volume":"38","author":"P Riederer","year":"1976","unstructured":"Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson\u2019s disease: a detailed study of influential factors in human brain amine analogues. J Neural Transm [P-D Sect] 38: 277\u2013301","journal-title":"J Neural Transm [P-D Sect]"},{"key":"2_CR190","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1471-4159.1989.tb09150.x","volume":"52","author":"P Riederer","year":"1989","unstructured":"Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J Neurochem 52: 515\u2013520","journal-title":"J Neurochem"},{"key":"2_CR191","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0304-3940(88)90292-3","volume":"94","author":"JO Rinne","year":"1988","unstructured":"Rinne JO, Halonen T, Riekinnen PJ, Rinne UK (1988) Free amino acids in the brain of patients with Parkinson\u2019s disease. Neurosci Lett 94: 182\u2013186","journal-title":"Neurosci Lett"},{"key":"2_CR192","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/jnnp.48.9.916","volume":"48","author":"JH Robbins","year":"1985","unstructured":"Robbins JH, Otsuka F, Nee LE (1985) Parkinson\u2019s disease and Alzheimer\u2019s disease: hypersensitivity to x-rays in cultured cell lines. J Neurol Neurosurg Psychiatry 48: 916\u2013923","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2_CR193","first-page":"203","volume-title":"Etiology of Parkinson\u2019s disease","author":"GC Roman","year":"1995","unstructured":"Roman GC, Zhang ZX, Ellenberg JH (1995) The neuroepidemiology of Parkinson\u2019s disease. In: Ellenberg JH, Koller WC, Langston JW (eds) Etiology of Parkinson\u2019s disease. Marcel Dekker, New York, pp 203\u2013243"},{"key":"2_CR194","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/362059a0","volume":"362","author":"DR Rosen","year":"1993","unstructured":"Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O\u2019Regan JP, Deng HX, et al (1993) Mutations in Cu\/Zn Superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59\u201362 (published erratum: Nature 364: 362)","journal-title":"Nature"},{"key":"2_CR195","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/0006-291X(91)92093-Y","volume":"181","author":"GM Rubanyi","year":"1991","unstructured":"Rubanyi GM, Ho EH, Cantor EH, Lumma WC, Botelho LH (1991) Cytoprotective function of nitric oxide: inactivation of Superoxide radicals produced by human leukocytes. Biochem Biophys Res Commun 181: 1392\u20131397","journal-title":"Biochem Biophys Res Commun"},{"key":"2_CR196","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1471-4159.1989.tb11759.x","volume":"53","author":"H Saggu","year":"1989","unstructured":"Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, Jenner P, Marsen CD (1989) A selective increase in particulate Superoxide dismutase activity in Parkinsonian sub-stantia nigra. J Neurochem 53: 692\u2013697","journal-title":"J Neurochem"},{"key":"2_CR197","first-page":"197","volume":"3","author":"JR Sanchez-Ramos","year":"1994","unstructured":"Sanchez-Ramos JR, \u00d6vervik E, Ames BN (1994) A marker of oxyradical-mediated DNA damage (8-hydroxy-2\u2032-deoxyguanosine) is increased in nigro-striatum of Parkinson\u2019s disease brain. Neurodegeneration 3: 197\u2013204","journal-title":"Neurodegeneration"},{"key":"2_CR198","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/ana.410320503","volume":"32","author":"GV Sawle","year":"1992","unstructured":"Sawle GV, Wroe SJ, Lees AJ, Brooks DJ, Frackowiak RS (1992) The identification of presymptomatic parkinsonism: clinical and [l8F]dopa positron emission tomography studies in an Irish kindred. Ann Neurol 32: 609\u2013617","journal-title":"Ann Neurol"},{"key":"2_CR199","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/mds.870090202","volume":"9","author":"AHV Schapira","year":"1994","unstructured":"Schapira AHV (1994) Evidence for mitochondrial dysfunction in Parkinson\u2019s disease \u2014 a critical appraisal. Mov Disord 9: 125\u201313","journal-title":"Mov Disord"},{"key":"2_CR200","first-page":"161","volume-title":"Advances in neurology, vol 69, Parkinson\u2019s disease","author":"AHV Schapira","year":"1996","unstructured":"Schapira AHV (1996) Neurotoxicity and the mechanisms of cell death in Parkinson\u2019s disease. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69, Parkinson\u2019s disease. Lippincott-Raven, Philadelphia, pp 161\u2013165"},{"key":"2_CR201","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00019052-199702000-00009","volume":"10","author":"AHV Schapira","year":"1997","unstructured":"Schapira AHV (1997) Mitochondrial disorders. Curr Opin Neurol 10: 43\u201347","journal-title":"Curr Opin Neurol"},{"key":"2_CR202","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/j.1471-4159.1990.tb05809.x","volume":"55","author":"AHV Schapira","year":"1990","unstructured":"Schapira AHV, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD (1990) Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson\u2019s disease. J Neurochem 55: 2142\u20132145","journal-title":"J Neurochem"},{"key":"2_CR203","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/ana.410260409","volume":"26","author":"D Scherman","year":"1989","unstructured":"Scherman D, Desnos C, Darchen F, Javoy-Agid F, Agid Y (1989) Striatal dopamine deficiency in Parkinson\u2019s disease: role of aging. Ann Neurol 26: 551\u2013557","journal-title":"Ann Neurol"},{"key":"2_CR204","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0006-2952(96)00452-2","volume":"13","author":"TA Seaton","year":"1996","unstructured":"Seaton TA, Marsden CD, Jenner P (1996) Mitochondrial respiratory enzyme function and Superoxide dismutase activity following brain glutathione depletion in the rat. Biochem Pharmacol 13: 1657\u20131663","journal-title":"Biochem Pharmacol"},{"key":"2_CR205","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/0006-8993(93)90505-H","volume":"611","author":"AP Sen","year":"1993","unstructured":"Sen AP, Boksa P, Quirion R (1993) Brain calcium channel-related dihydropyridine and phenylalkylamine binding sites in Alzheimer\u2019s, Parkinson\u2019s and Huntington\u2019s diseases. Brain Res 611: 216\u2013221","journal-title":"Brain Res"},{"key":"2_CR206","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/0361-9230(92)90118-H","volume":"28","author":"GJ Sengstock","year":"1992","unstructured":"Sengstock GJ, Olanow CW, Dunn AJ, Arendash GW (1992) Iron induces degeneration of nigrostriatal neurons. Brain Res Bull 28: 645\u2013649","journal-title":"Brain Res Bull"},{"key":"2_CR207","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1006\/exnr.1994.1187","volume":"130","author":"GJ Sengstock","year":"1994","unstructured":"Sengstock GJ, Olanow CW, Dunn AJ, Barone S, Arendash GW (1994) Progressive changes in striatal dopaminergic markers, nigral volume and rotational behavior following iron infusion into rat substantia nigra. Exp Neurol 130: 82\u201394","journal-title":"Exp Neurol"},{"key":"2_CR208","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/ana.410360306","volume":"36","author":"J Sian","year":"1994","unstructured":"Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD (1994) Glutathione-related enzymes in brain in Parkinson\u2019s disease. Ann Neurol 36: 356\u2013361","journal-title":"Ann Neurol"},{"key":"2_CR209","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000117184","volume":"30","author":"BK Siesj\u00f6","year":"1990","unstructured":"Siesj\u00f6 BK (1990) Calcium in the brain under physiological and pathological conditions. Eur Neurol 30: 3\u20139","journal-title":"Eur Neurol"},{"key":"2_CR210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1471-4159.1987.tb03384.x","volume":"49","author":"TP Singer","year":"1987","unstructured":"Singer TP, Castagnoli N, Ramsay RR, Trevor AJ (1987) Biochemical events in the development of parkinsonism induced by of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 49: 1\u20138","journal-title":"J Neurochem"},{"key":"2_CR211","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1097\/00007611-199612000-00008","volume":"89","author":"TA Smith","year":"1996","unstructured":"Smith TA, Prayson RA (1996) Lewy body disease. South Med J 89: 1174\u20131180","journal-title":"South Med J"},{"key":"2_CR212","first-page":"449","volume-title":"Advances in neurology, vol 69, Parkinson\u2019s disease","author":"BJ Snow","year":"1996","unstructured":"Snow BJ (1996) Fluorodopa PET scanning in Parkinson\u2019s disease. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69, Parkinson\u2019s disease. Lippincott-Raven, Philadelphia, pp 449\u2013457"},{"key":"2_CR213","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF01244786","volume":"74","author":"E Sofic","year":"1988","unstructured":"Sofic E, Riederer P, Heinsen H, Beckman H, Reynolds GP, Hebenstreit G, Youdim MBH (1988) Increased iron(III) and total iron content in post mortem substantia nigra of Parkinsonian brain. J Neural Transm 74: 199\u2013205","journal-title":"J Neural Transm"},{"key":"2_CR214","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0304-3940(92)90355-B","volume":"142","author":"E Sofic","year":"1992","unstructured":"Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson\u2019s disease. Neurosci Lett 142: 128\u2013130","journal-title":"Neurosci Lett"},{"key":"2_CR215","first-page":"283","volume":"46","author":"KH Sontag","year":"1995","unstructured":"Sontag KH, Heim C, Sontag TA, God R, Reichmann H, Wesemann W, Rausch WD, Riederer, Bringmann G (1995) Long-term behavioural effects of TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-\u03b2-carboline) after subchronic treatment in rats. J Neural Transm [Suppl] 46: 283\u2013289","journal-title":"J Neural Transm [Suppl]"},{"key":"2_CR216","first-page":"319","volume-title":"Etiology of Parkinson\u2019s disease","author":"PS Spencer","year":"1995","unstructured":"Spencer PS, Butterfield PG (1995) Environmental agents and Parkinson\u2019s disease. In: Ellenberg JH, Koller WC, Langston JW (eds) Etiology of Parkinson\u2019s disease. Marcel Dekker, New York, pp 319\u2013365"},{"key":"2_CR217","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1126\/science.3603037","volume":"237","author":"PS Spencer","year":"1987","unstructured":"Spencer PS, Nunn PB, Hugon J, Ludolph AC, Ross SM, Roy DN, Robertson RC (1987) Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science 237: 517\u2013522","journal-title":"Science"},{"key":"2_CR218","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0014-5793(94)01056-0","volume":"353","author":"JPE Spencer","year":"1994","unstructured":"Spencer JPE, Jenner A, Aruoma OI, Evans PJ, Kaur H, Dexter DT, Jenner P, Lees AJ, Marsden DC, Halliwell B (1994) Intense oxidative DNA damage promoted by l-dopa and its metabolites: implications for neurodegenerative disease. FEBS Lett 353: 246\u2013250","journal-title":"FEBS Lett"},{"key":"2_CR219","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/00001756-199404000-00039","volume":"5","author":"T Spencer-Smith","year":"1994","unstructured":"Spencer-Smith T, Parker WD, Bennett JP (1994) L-Dopa increases nigral production of hydroxyl radicals in vivo: potential 1-dopa toxicity? Neuroreport 5: 1009\u20131011","journal-title":"Neuroreport"},{"key":"2_CR220","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R. Goedert M (1997) \u03b1-synuclein in Lewy bodies (letter). Nature 388: 839\u2013840","journal-title":"Nature"},{"key":"2_CR221","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.86.4.1398","volume":"88","author":"MB Spina","year":"1989","unstructured":"Spina MB, Cohen G (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson\u2019s disease. Proc Natl Acad Sci USA 88: 1398\u20131400","journal-title":"Proc Natl Acad Sci USA"},{"key":"2_CR222","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1006\/exnr.1994.1091","volume":"127","author":"JE Springer","year":"1994","unstructured":"Springer JE, Mu X, Bergmann LW, Trojanowsky Q (1994) Expression of GDNF mRNA in rat and human nervous tissue. Exp Neurol 127: 167\u2013170","journal-title":"Exp Neurol"},{"key":"2_CR223","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1749-6632.1963.tb42905.x","volume":"100","author":"GA Swan","year":"1963","unstructured":"Swan GA (1963) Chemical structure of melanins. Ann NY Acad Sci 100: 1005","journal-title":"Ann NY Acad Sci"},{"key":"2_CR224","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1002\/ana.410320712","volume":"32","author":"HM Swartz","year":"1992","unstructured":"Swartz HM, Sarna T, Zecca L (1992) Modulation by neuromelanin of the availability and reactivity of metal ions. Ann Neurol 32 [Suppl]: S69\u2013S75","journal-title":"Ann Neurol"},{"key":"2_CR225","first-page":"290","volume":"26","author":"D Taussig","year":"1997","unstructured":"Taussig D, Plante-Bordeneuve V (1997) Les syndromes parkinsoniens familiaux \u201catypiques\u201d. Maladies de Parkinson ou entites autonomes? Presse Med 26: 290\u2013296","journal-title":"Presse Med"},{"key":"2_CR226","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1471-4159.1994.62010134.x","volume":"62","author":"JA Temlet","year":"1994","unstructured":"Temlet JA, Landsberg JP, Watt F, Grime GW (1994) Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J Neurochem 62: 134\u2013146","journal-title":"J Neurochem"},{"key":"2_CR227","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1471-4159.1993.tb13610.x","volume":"61","author":"KF Tipton","year":"1993","unstructured":"Tipton KF, Singer TP (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61: 1191\u20131206","journal-title":"J Neurochem"},{"key":"2_CR228","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF01271295","volume":"104","author":"S Toffa","year":"1997","unstructured":"Toffa S, Kunikowska GM, Zeng BY, Jenner P, Marsden CD (1997) Chronic glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. J Neural Transm [PD Sect] 104: 67\u201375","journal-title":"J Neural Transm [PD Sect]"},{"key":"2_CR229","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/373335a0","volume":"373","author":"A Tomac","year":"1995","unstructured":"Tomac A, Lindquist E, Lin LFH, \u00d6gren SO, Young D, Hoffer BJ, Olsen L (1995) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373: 335\u2013339","journal-title":"Nature"},{"key":"2_CR230","first-page":"119","volume":"150","author":"MM Tompkins","year":"1997","unstructured":"Tompkins MM, Basgall EJ, Zamrini E, Hill WD (1997) Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol 150: 119\u2013131","journal-title":"Am J Pathol"},{"key":"2_CR231","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1212\/WNL.43.2.372","volume":"43","author":"I Tooyama","year":"1993","unstructured":"Tooyama I, Kawamata T, Walker D, Yamada I, Hanai K, Kimura H, Iwane M, Igarashi K, McGeer EG, McGeer PL (1993) Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson\u2019s disease. Neurology 43: 372\u2013376","journal-title":"Neurology"},{"key":"2_CR232","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/349414a0","volume":"349","author":"L Turski","year":"1991","unstructured":"Turski L, Bressler K, Rettig KJ, L\u00f6schmann PA, Wachtel H (1991) Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-d-aspartate antagonists. Nature 349: 414\u2013418","journal-title":"Nature"},{"key":"2_CR233","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02250916","volume":"8","author":"P Vieregge","year":"1994","unstructured":"Vieregge P (1994) Genetic factors in the etiology of Parkinson\u2019s disease. J Neural Transm 8: 1\u201337","journal-title":"J Neural Transm"},{"key":"2_CR234","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1172\/JCI117946","volume":"95","author":"G Walinshaw","year":"1995","unstructured":"Walinshaw G, Waters CM (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-dopa: imolications for the treatment of Parkinson\u2019s disease. J Clin Invest 95: 2458\u20132464","journal-title":"J Clin Invest"},{"key":"2_CR235","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1126\/science.1533953","volume":"256","author":"DC Wallace","year":"1992","unstructured":"Wallace DC (1992a) Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science 256: 628\u2013632","journal-title":"Science"},{"key":"2_CR236","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1146\/annurev.bi.61.070192.005523","volume":"61","author":"DC Wallace","year":"1992","unstructured":"Wallace DC (1992b) Diseases of the mitochondrial DNA Ann Rev Biochem 61: 1175\u20131212","journal-title":"Ann Rev Biochem"},{"key":"2_CR237","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ana.410350110","volume":"35","author":"CH Waters","year":"1994","unstructured":"Waters CH, Miller CA (1994) Autosomal dominant Lewy body parkinsonism in a four-generation family. Ann Neurol 35: 59\u201364","journal-title":"Ann Neurol"},{"key":"2_CR238","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF02260941","volume":"8","author":"W Wesemann","year":"1994","unstructured":"Wesemann W, Blaschke S, Solbach M, Grote C, Clement HW, Riederer P (1994) Intranigral injected iron progressively reduces striatal dopamine metabolism. J Neural Transm [PD Sect] 8: 209\u2013214","journal-title":"J Neural Transm [PD Sect]"},{"key":"2_CR239","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00001756-199603220-00018","volume":"7","author":"U W\u00fcllner","year":"1996","unstructured":"W\u00fcllner U, L\u00f6schmann PA, Schulz JB, Schmid A, Dringen R, Eblen F, Turski L. Klockgether T (1996) Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones. Neuroreport 7: 921\u2013923","journal-title":"Neuroreport"},{"key":"2_CR240","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0006-8993(90)91236-A","volume":"526","author":"T Yamada","year":"1990","unstructured":"Yamada T, McGeer PL, Baimbridge KG, McGeer EG (1990) Relative sparing in Parkinson\u2019s disease of substantia nigra neurons containing calbindin D28K. Brain Res 526: 303\u2013307","journal-title":"Brain Res"},{"key":"2_CR241","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/0006-291X(89)92701-0","volume":"165","author":"TC Yen","year":"1989","unstructured":"Yen TC, Chen YS, King KL, Yeh SH, Wei YH (1989) Liver mitochondrial functions decline with age. Biochem Biophys Res Commun 165: 994\u20131003","journal-title":"Biochem Biophys Res Commun"},{"key":"2_CR242","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1073\/pnas.93.7.2696","volume":"93","author":"A Yoritaki","year":"1996","unstructured":"Yoritaki A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson\u2019s disease. Proc Natl Acad Sci USA 93: 2696\u20132713","journal-title":"Proc Natl Acad Sci USA"},{"key":"2_CR243","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0022-510X(94)90006-X","volume":"124","author":"E Yoshida","year":"1994","unstructured":"Yoshida E, Mokuno K, Aoki SI, Takahashi A, Riku S, Murayama T, Yanagi T, Kato K (1994) Cerebrospinal fluid levels of Superoxide dismutases in neurological diseases detected by sensitive enzyme immunoassays. J Neurol Sci 124: 25\u201331","journal-title":"J Neurol Sci"},{"key":"2_CR244","first-page":"113","volume":"43","author":"MBH Youdim","year":"1994","unstructured":"Youdim MBH, Ben-Shachar D, Riederer P (1994) The enigma of neuromelanin in Parkinson\u2019s disease substantia nigra. J Neural Transm [Suppl] 43: 113\u2013132","journal-title":"J Neural Transm [Suppl]"}],"container-title":["Journal of Neural Transmission. Supplementa","Diagnosis and Treatment of Parkinson\u2019s Disease \u2014 State of the Art"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-7091-6360-3_2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T01:30:18Z","timestamp":1744248618000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-7091-6360-3_2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999]]},"ISBN":["9783211832752","9783709163603"],"references-count":244,"URL":"https:\/\/doi.org\/10.1007\/978-3-7091-6360-3_2","relation":{},"ISSN":["0303-6995"],"issn-type":[{"value":"0303-6995","type":"print"}],"subject":[],"published":{"date-parts":[[1999]]}}}